Back to Search
Start Over
Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential
- Source :
- Journal of Opioid Management. 12:139-147
- Publication Year :
- 2016
- Publisher :
- Weston Medical Publishing, 2016.
-
Abstract
- Objective: To evaluate long-term safety, maintenance of analgesia, and aberrant drug-related behaviors of hydrocodone extended release (ER) formulated with CIMA ® Abuse-Deterrence Technology. Design: Phase 3, multicenter, open-label extension. Setting: Fifty-six US centers. Patients: Adults with chronic low back pain completing a 12-week placebo-controlled study of abuse-deterrent hydrocodone ER were eligible. One hundred eighty-two patients enrolled and received ≥ 1 dose of study drug, 170 entered open-label treatment, and 136 completed the study. Interventions: Patients receiving hydrocodone ER in the 12-week, placebo-controlled study continued their previous dose unless adjustment was needed; those previously receiving placebo (n = 78) underwent dose titration/adjustment to an analgesic dose (15-90 mg every 12 hours). Patients received 22 weeks of open-label treatment. Main outcome measures: Safety: adverse events (AEs). Maintenance of analgesia: worst pain intensity (WPI) and average pain intensity (API) at each study visit. Aberrant drug behavior: study drug loss and diversion. Results: AEs were reported for 65/182 (36 percent) patients during dose titration/adjustment and 88/170 (52 percent) during open-label treatment. No treatment-related serious AEs were reported. There were no clinically meaningful trends in other safety assessments, including physical examinations and pure tone audiometry. One patient receiving hydrocodone ER 30 mg twice daily experienced a severe AE of neurosensory deafness that was considered treatment related. Mean WPI and API remained steady throughout open-label treatment. Six (3 percent) patients reported medication loss, and 5 (3 percent) reported diversion. Conclusions: Abuse-deterrent hydrocodone ER was generally well tolerated in patients with chronic low back pain, maintained efficacy, and was associated with low rates of loss and diversion.
- Subjects :
- Adult
Male
Time Factors
Prescription Drug Diversion
Chemistry, Pharmaceutical
Analgesic
Placebo
Drug Administration Schedule
law.invention
03 medical and health sciences
0302 clinical medicine
Double-Blind Method
Randomized controlled trial
Risk Factors
law
medicine
Humans
Pharmacology (medical)
Hydrocodone
030212 general & internal medicine
Adverse effect
Prescription Drug Misuse
Aged
Pain Measurement
medicine.diagnostic_test
business.industry
Chronic pain
General Medicine
Middle Aged
Opioid-Related Disorders
medicine.disease
United States
Analgesics, Opioid
Clinical trial
Treatment Outcome
Anesthesiology and Pain Medicine
Delayed-Action Preparations
Anesthesia
Female
Pure tone audiometry
Chronic Pain
business
Low Back Pain
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 15517489
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- Journal of Opioid Management
- Accession number :
- edsair.doi.dedup.....f16498d7ec0d8de55fc9b7c3a5c372a5